This is a randomized, double blind, placebo-controlled study of the effects of intranasal
oxytocin in obese adults, ages 18-45 years old. Subjects will be randomized to receive of
intranasal oxytocin or placebo (3 sprays per nostril, 4 times per day) for 8 weeks. Study
visits include screening to determine eligibility, a 2-part baseline visit, and visits every
2 weeks thereafter until week 14, with a safety follow-up visit 6 weeks after the last dose
of study drug. Study procedures include behavioral, metabolic, neuroimaging, and endocrine
assessments.